Skip to main content

Table 2 Association of MGMT promoter methylation and MGMT and CD133 expression in human GBM

From: MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy

   Total Methylated Unmethylated Not done
MGMT expression      
Low-expression +/−, + 42 (55.3%) 20 (26.3%) 22 (29%) 2 (2.6%)
High-expression ++, +++ 34 (44.7%) 14 (18.4%) 20 (26.3%)  
CD133 expression      
Low-expression +/−, + 41 (54.7%) 16 (21.3%) 25 (33.4%) 3 (4%)
High-expression ++, +++ 34 (45.3%) 18 (24%) 16 (21.3%)  
  1. Data are represented as the percentage of the total of analyzed patients.